Publications

Infection of inbred strains of mice with Leishmania major is a well-characterized model for analysis of the development of effector CD4+ subsets of the Th1 and Th2 types in vivo. We co-administered a fusion protein, CTLA4Ig, that blocks the CD28-B7 costimulatory pathway important for optimal T cell activation, to assess the relative role for this pathway during maturation of Th1 and Th2 cells in vivo. Surprisingly, CTLA4Ig administered within the first week of infection completely abrogated progressive disease in susceptible BALB/c mice while having no effect on the protective immune response developed by resistant C57BL/6 mice. The protective effect in BALB/c mice was increasingly lost if administration of CTLA4Ig was delayed longer than 1 wk after infection. As in other protective interventions used in this model, control of infection was associated with down-regulation of IL-4 mRNA transcripts in lymph node cells recovered 5 wk after infection together with abrogation of IgE production and enhanced parasite-specific IgG2a relative to IgG1. Although a single dose of CTLA4Ig was protective, sustained delivery abolished the capacity of BALB/c mice to contain infection, suggesting that costimulation through this pathway is required at later stages of the immune response. Taken together, the data demonstrate that the priming of Th2 cells is more dependent upon the CD28-B7 pathway than the priming of Th1 cells, and suggest that the development of Th subsets in vivo may be influenced by limiting CD28-B7 costimulation.

Subcutaneous administration of CoCl2, a well recognized inhibitor of hepatic heme synthesis, to rats results in the functional stimulation of total (holo- + apo) tryptophan 2,3 dioxygenase (TDO), a hemoprotein and the key rate-limiting enzyme in the oxidative metabolism of tryptophan to formylkynurenine. Because basal holo-TDO activity is not altered, TDO stimulation appears to be entirely due to CoCl2-mediated increase of its apoprotein. This apoTDO increase was blocked by conventional inhibitors of protein synthesis (actinomycin D, cycloheximide), thereby revealing that such CoCL2-mediated apoprotein increase truly reflected TDO induction. To determine whether the CoCl2-mediated TDO induction involved the action of its natural physiological inducers (glucocorticoids) or was due to direct CoCl2-regulation of the TDO gene, rats were adrenalectomized before CoCl2 administration. In adrenalectomized rats, CoCl2 failed to induce TDO, but induction was completely restored on administration of the glucocorticoid hydrocortisone, but not of adrenaline. These findings reveal that CoCl2-mediated TDO induction is indirect and entails glucocorticoid participation. In addition, because CoCl2 lowered the % heme saturation of TDO [= 100(holo TDO activity/total (apo+holo) TDO activity] largely by increasing the apoTDO protein levels rather than by affecting the basal holo-TDO levels (as expected from its inhibition of heme synthesis), these findings question the widely accepted use of the relative intrahepatic % heme saturation of TDO as a reporter of the hepatic "free" heme pool.

We have previously reported the sequence of the integrin alpha 9 subunit, a partner of the beta 1 subunit that is expressed in basal keratinocytes, hepatocytes, airway epithelial cells, and smooth and skeletal muscle. In the present study, we have stably expressed alpha 9 beta 1 on the surface of the human embryonic kidney cell line 293 and the human colon carcinoma cell line SW480 and used these transfected cells lines to identify ligand(s) for this integrin. Transfected cells did not appear to utilize alpha 9 beta 1 for attachment to the extracellular matrix proteins fibronectin, laminin, vitronectin, fibrinogen, thrombospondin, or type I or IV collagen. However, in contrast to mock transfectants, both 293 cells and SW480 cells expressing alpha 9 beta 1 adhered to intact chicken tenascin. By utilizing a variety of recombinant fragments of tenascin, we were able to localize the binding site for alpha 9 beta 1 to the third type III repeat. This repeat contains the arginine-glycine-aspartic acid (RGD) tripeptide that has been shown to serve as a binding site in tenascin for alpha v-integrins. However, the RGD site does not appear to be the binding site for alpha 9 beta 1, as the attachment of alpha 9 transfectants to this fragment was not inhibited by RGD peptide, nor by changing the RGD site to RAD or RAA.